Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy
The median rwOS for this study was comparable with results in the VIALE-A trial, despite the community-based nature of these data. There was no clear standard of care for patients who received 2L+ therapy. These data highlight the need for novel treatment for patients with AML following 1L VEN-based therapy.
Authors
- Henry F. Owusu (ORCID: https://orcid.org/0000-0003-2492-0947)
- Eric Hansen (ORCID: https://orcid.org/0000-0003-2829-1316)
- Ronan Swords (ORCID: https://orcid.org/0000-0003-3319-1870)
- Ching‐Kun Wang
- Anna Barcellos (ORCID: https://orcid.org/0000-0002-2168-7919)
- Andrew J. Belli
- Eytan M. Stein (ORCID: https://orcid.org/0000-0001-8992-9390)
- Amer Methqal Zeidan (ORCID: https://orcid.org/0000-0001-7017-8160)
- Christina M. Zettler (ORCID: https://orcid.org/0000-0002-7516-593X)
- Laura L. Fernandes (ORCID: https://orcid.org/0000-0002-5986-3885)
- Curtis A. Lachowiez (ORCID: https://orcid.org/0000-0001-8506-0624)
Institutions
- Novartis (Switzerland) (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Oregon Health & Science University (US)
- Yale Cancer Center (US)
- Yale University (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1200/op-24-00983
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54